AR005646A1 - Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos - Google Patents
Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentosInfo
- Publication number
- AR005646A1 AR005646A1 ARP970100184A ARP970100184A AR005646A1 AR 005646 A1 AR005646 A1 AR 005646A1 AR P970100184 A ARP970100184 A AR P970100184A AR P970100184 A ARP970100184 A AR P970100184A AR 005646 A1 AR005646 A1 AR 005646A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- pharmaceutical preparations
- nr6r7
- quinolein
- medicines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El invento se refiere a los derivados de la quinoleín-2-(1H)-ona de la fórmula (I) en donde R1, R2 y R3 representan independientemente H, Hal, A o OA,R4 es H, -(CH2)m-NR6R7; R5 es H,-(CH2)n-NR6R7; R6 es H, A, o junto con R7 es - (CH2)4 - o-(CH 2)5-; X es -CHR5-, NR5-, -O-, -S-,; A es alquilo de 1 a 6 átomosde C, Hal es F, Cl, Br o I, m es un número del 1 a 3 y n es un número del 0 al 3, y en donde al menos uno de los restos R4 o R5 significa -(CH2)m-NR6R7 o- (CH(CH2)n-NR6R7, a sussales y productos de solvatación. El invento también se refiere a un procedimiento para preparar estos compuestos y sus salesaceptables desde el punto de vista fisiológico, a preparaciones farmacéuticas que los contienen y al empleo de losmismos para el tratamiento de lasmodificaciones neurodegenerativas de las funciones del sistema nervioso central.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19601782A DE19601782A1 (de) | 1996-01-19 | 1996-01-19 | Chinolin-2-(1H)one |
Publications (1)
Publication Number | Publication Date |
---|---|
AR005646A1 true AR005646A1 (es) | 1999-07-14 |
Family
ID=7783141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100184A AR005646A1 (es) | 1996-01-19 | 1997-01-17 | Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos |
Country Status (18)
Country | Link |
---|---|
US (1) | US6028080A (es) |
EP (1) | EP0885196A1 (es) |
JP (1) | JP2000503308A (es) |
KR (1) | KR19990077308A (es) |
CN (1) | CN1211974A (es) |
AR (1) | AR005646A1 (es) |
AU (1) | AU716230B2 (es) |
BR (1) | BR9707027A (es) |
CA (1) | CA2243474C (es) |
CZ (1) | CZ224098A3 (es) |
DE (1) | DE19601782A1 (es) |
HU (1) | HUP9900563A3 (es) |
MX (1) | MX9805700A (es) |
NO (1) | NO983333L (es) |
PL (1) | PL327829A1 (es) |
SK (1) | SK93198A3 (es) |
WO (1) | WO1997026244A1 (es) |
ZA (1) | ZA97364B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0015320A (pt) * | 1999-11-03 | 2002-07-09 | Albany Molecular Res Inc | Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US7166738B2 (en) * | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
US7625949B2 (en) | 2004-04-23 | 2009-12-01 | Roche Palo Alto Llc | Methods for treating retroviral infections |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
WO2009123241A1 (ja) | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
JP2011518130A (ja) * | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト |
GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
KR101762574B1 (ko) | 2009-03-31 | 2017-07-28 | 가부시키가이샤 레나사이언스 | 플라즈미노겐 액티베이터 인히비터-1 저해제 |
JP2013516475A (ja) | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | Dp2アンタゴニストおよびその使用 |
WO2014171464A1 (ja) | 2013-04-15 | 2014-10-23 | 株式会社レナサイエンス | Pai-1阻害剤の新規用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0459561B1 (en) * | 1990-05-31 | 1995-09-20 | MERCK SHARP & DOHME LTD. | Dioxo-tetrahydroquinoline derivatives |
US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
GB9022785D0 (en) * | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
GB9125515D0 (en) * | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
EP0685466A1 (de) * | 1994-06-02 | 1995-12-06 | Ciba-Geigy Ag | 3-Heteroaliphatyl- und 3-Hetero-(aryl)aliphatyl-2(1H)-chinolonderivate |
-
1996
- 1996-01-19 DE DE19601782A patent/DE19601782A1/de not_active Withdrawn
-
1997
- 1997-01-10 SK SK931-98A patent/SK93198A3/sk unknown
- 1997-01-10 JP JP9525656A patent/JP2000503308A/ja not_active Withdrawn
- 1997-01-10 CN CN97192395A patent/CN1211974A/zh active Pending
- 1997-01-10 EP EP97900586A patent/EP0885196A1/de not_active Withdrawn
- 1997-01-10 WO PCT/EP1997/000084 patent/WO1997026244A1/de not_active Application Discontinuation
- 1997-01-10 KR KR1019980705454A patent/KR19990077308A/ko not_active Application Discontinuation
- 1997-01-10 BR BR9707027A patent/BR9707027A/pt unknown
- 1997-01-10 CZ CZ982240A patent/CZ224098A3/cs unknown
- 1997-01-10 HU HU9900563A patent/HUP9900563A3/hu unknown
- 1997-01-10 US US09/101,837 patent/US6028080A/en not_active Expired - Fee Related
- 1997-01-10 AU AU13112/97A patent/AU716230B2/en not_active Ceased
- 1997-01-10 PL PL97327829A patent/PL327829A1/xx unknown
- 1997-01-10 CA CA002243474A patent/CA2243474C/en not_active Expired - Fee Related
- 1997-01-16 ZA ZA97364A patent/ZA97364B/xx unknown
- 1997-01-17 AR ARP970100184A patent/AR005646A1/es unknown
-
1998
- 1998-07-15 MX MX9805700A patent/MX9805700A/es unknown
- 1998-07-17 NO NO983333A patent/NO983333L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP9900563A2 (hu) | 1999-06-28 |
NO983333L (no) | 1998-09-18 |
CZ224098A3 (cs) | 1998-10-14 |
CA2243474A1 (en) | 1997-07-24 |
MX9805700A (es) | 1998-11-29 |
BR9707027A (pt) | 1999-07-20 |
US6028080A (en) | 2000-02-22 |
NO983333D0 (no) | 1998-07-17 |
CN1211974A (zh) | 1999-03-24 |
PL327829A1 (en) | 1999-01-04 |
EP0885196A1 (de) | 1998-12-23 |
AU716230B2 (en) | 2000-02-24 |
AU1311297A (en) | 1997-08-11 |
JP2000503308A (ja) | 2000-03-21 |
SK93198A3 (en) | 1999-01-11 |
WO1997026244A1 (de) | 1997-07-24 |
DE19601782A1 (de) | 1997-07-24 |
ZA97364B (en) | 1997-07-22 |
KR19990077308A (ko) | 1999-10-25 |
CA2243474C (en) | 2009-10-27 |
HUP9900563A3 (en) | 2000-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR005646A1 (es) | Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos | |
SE9001329L (sv) | Adamantanderivat foer att foerhindra och behandla cerebral ischemi | |
AR009052A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas | |
PT89623A (pt) | Processo de preparacao de derivados de indolcarbazolo e de composicoes farmaceuticas contendo esses compostos | |
NZ223772A (en) | Substituted benzodiazepine derivatives and pharmaceutical compositions | |
ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
AR009985A1 (es) | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
HN1998000074A (es) | Derivados de macrolidos c-4 sustituidos | |
AR009069A1 (es) | Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
AR007969A1 (es) | Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos | |
IL102354A (en) | Pharmaceutically active hydrazine derivatives and process for the preparation thereof | |
AR010962A1 (es) | Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas. | |
ES2118203T3 (es) | Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
BR9812239A (pt) | Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto | |
ES2115904T3 (es) | Derivados amino ramificados del tiazol, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen. | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
ES2103440T3 (es) | Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
IL101514A0 (en) | Cholecystokinin antagonists and pharmaceutical compositions containing them | |
ES2125963T3 (es) | Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen. | |
MX9400165A (es) | Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. | |
ES2122221T3 (es) | Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ES2065192T3 (es) | Nuevos nicotinatos de diacil-glicerol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
SE9203824L (sv) | Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma | |
ES2095714T3 (es) | Nuevas amino-alquil-cromonas, sus procedimientos de preparacion y las composiciones farmaceuticas que las contienen. | |
ES2053590T3 (es) | 3-fenil-7h-tiazolo(3,2-b)(1,2,4)triazin-7-onas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y su empleo, asi como algunos productos intermedios formados durante la preparacion de los compuestos mencionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |